Oyster Point's (OYST) Tyrvaya Gets FDA Nod for Dry Eye Disease

Zacks Equity Research
2 min read
0

Oyster Point Pharma, Inc. OYST announced that the FDA has approved its nasal spray Tyrvaya (varenicline solution) for the treatment of patients with signs and symptoms of dry eye disease.

Following the FDA nod, Tyrvaya became the first and only nasal spray to be approved for the given indication. Tyrvaya nasal spray will hit the market in the United States from next month.

The approval of Tyrvaya (0.03 mg) nasal spray was based on data from several studies that evaluated more than 1,000 patients with mild, moderate or severe dry eye disease. Tyrvaya nasal spray was investigated in the ONSET-1, ONSET-2 and MYSTIC clinical studies.

Patients who were treated with Tyrvaya nasal spray demonstrated statistically significant improvements in tear film production as seen using the anesthetized Schirmer's score at week four of treatment.

Shares of Oyster Point have plunged 26.3% so far this year compared with the industry’s decline of 10.9%.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

Last December, the company submitted the new drug application for Tyrvaya nasal spray to the FDA for the treatment of signs and symptoms of dry eye disease.

We note that Oyster Point is focused on the development and commercialization of first-in-class therapies to address ophthalmic diseases. The company is also evaluating Tyrvaya nasal spray in the phase II OLYMPIA study for the treatment of stage 1 neurotrophic keratopathy, a rare corneal disease.

Till now, Oyster Point has had no approved product in its portfolio. As a result, the successful commercialization of Tyrvaya remains critical for the company’s long-term growth as it will able to generate revenues from product sales.

Zacks Rank & Stocks to Consider

Oyster Point currently carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the biotech sector include Fulcrum Therapeutics, Inc. FULC, Athenex, Inc. ATNX and Amicus Therapeutics, Inc. FOLD, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Fulcrum Therapeutics’ loss per share estimates have narrowed 7.4% for 2021 and 10% for 2022, over the past 60 days. The stock has soared 96.8% year to date.

Athenex’s loss per share estimates have narrowed 9% for 2021 and 9.2% for 2022, over the past 60 days.

Amicus Therapeutics’ loss per share estimates have narrowed 1.3% for 2021 and 37.5% for 2022, over the past 60 days.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Amicus Therapeutics, Inc. (FOLD) : Free Stock Analysis Report

Athenex, Inc. (ATNX) : Free Stock Analysis Report

Fulcrum Therapeutics, Inc. (FULC) : Free Stock Analysis Report

OYSTER PT PHARM (OYST) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Advertisement

Recommended Stories

  • Jeff Bezos' Most Prized Possession Breaks Historical Auction Records At Almost $53 Million

    Jeff Bezos amassed his wealth through Amazon stocks and owns hundreds of millions of dollars worth of real estate, but one of his most valuable possessions may surprise you: art. Among his collection is the renowned piece "Hurting the Word Radio #2 (1964)" by Ed Ruscha, purchased by Bezos for almost $53 million. This artwork, a prime example of Ruscha’s text-based paintings, stands as a signature piece in Bezos’ collection. As concerns over stock market volatility persist, the world’s wealthiest

  • Warren Buffett's Latest $2.6 Billion Buy Brings His Total Investment in This Stock to More Than $77 Billion in Under 6 Years

    The Oracle of Omaha has purchased shares of his favorite stock for 23 consecutive quarters.

  • Bluesky now lets you personalize main Discover feed using new controls

    Bluesky is now allowing users to personalize their main Discover feeds. The social network is rolling out an updated version of its app that lets users offer feedback about its algorithmic feed so they can better customize it using "Show more like this" and "Show less like this" buttons in a post's menu to choose which content the algorithm surfaces. The change will help Bluesky users create a timeline that takes into consideration their own preferences, not what the company thinks they should see.

  • Anthropic now lets kids use its AI tech -- within limits

    AI startup Anthropic is changing its policies to allow minors to use its generative AI systems -- in certain circumstances, at least. Announced in a post on the company's official blog Friday, Anthropic will begin letting teens and preteens use third-party apps (but not its own apps, necessarily) powered by its AI models so long as the developers of those apps implement specific safety features and disclose to users which Anthropic technologies they're leveraging. In a support article, Anthropic lists several safety measures devs creating AI-powered apps for minors should include, like age verification systems, content moderation and filtering and educational resources on "safe and responsible" AI use for minors.

  • With Apple entering the fight, the AI chip wars have gone nuclear

    The AI PC chip wars are going nuclear as Apple officially joins the fight with its M4 processor.

  • I Finally Decided to Cut My Losses and Sell This Stock -- Here's Why

    This real estate technology company could be hit hard by a changing real estate market.

  • Bitcoin Is In a 'Bore You to Death' Phase, but Bottom Could Be Close, Analysts Say

    The current boring crypto market could last between one to six months, and the sentiment will be the most negative right before the turnaround, one hedge fund manager said.

  • 3 Rock-Solid Dividend Stocks That Are Ideal for Retirees

    These are low-risk stocks with high yields.

  • Palantir Stock (NYSE:PLTR): Should You Buy the Post-Earnings Dip?

    Palantir stock (NYSE:PLTR) dipped by about 16% after its Q1 earnings report, prompting me to ponder whether this downturn presents a buying opportunity. Notably, Palantir showcased yet another quarter of solid revenue growth, promising client base expansion, and strong profitability metrics. That said, concerns persist regarding the stock’s elevated valuation. Consequently, despite my belief in Palantir’s long-term prospects as a shareholder, I maintain a neutral stance towards the stock at pres

  • McDonald’s Will Offer a $5 Meal Deal to Lure Customers Back Into Stores

    (Bloomberg) -- McDonald’s Corp. is looking to launch a $5 meal deal in the US that the burger chain is betting can lure penny-pinching consumers back in.Most Read from BloombergElon Musk Pledges to Grow Supercharger Business He Just DecimatedApple Nears Deal With OpenAI to Put ChatGPT on iPhoneBiden Set to Hit China EVs, Strategic Sectors With TariffsJim Simons, Code Breaker Who Mastered Investing, Dies at 86Ice Cube’s Big3 Basketball League Sells Its First Team in $10 Million DealThe deal could